anti-cd33 car-nk cells
Cell therapyexperimental
Clinical trial activity
4 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2016 (NCT02944162)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Myeloid cell surface antigen CD33Immunity, passive
CD33 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-cd33 car-nk cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05987696 | Phase 1 | Aug 10, 2023 | China Academy of Chinese Medical Sciences, Hangzhou Qihan Biotech Co.,Ltd. |
| NCT05008575 | Phase 1 | Sep 1, 2021 | People's Liberation Army of China, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Xinqiao Hospital of Chongqing |
| NCT05215015 | Early Phase 1 (Phase 1) | Nov 30, 2020 | Imbioray (Hangzhou) Biomedicine Co., Ltd., Wuxi People's Hospital |
| NCT02944162 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2016 | Hefei University, PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Hangzhou Qihan Biotech Co.,Ltd. | For profit | 1 | 0 | 1 | 2023 |
| Hefei University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Imbioray (Hangzhou) Biomedicine Co., Ltd. | For profit | 1 | 0 | 1 | 2020 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2021 |
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | For profit | 1 | 1 | 1 | 2016 |
| Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | For profit | 1 | 0 | 1 | 2021 |
| Wuxi People's Hospital | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Xinqiao Hospital of Chongqing | Academic/Hospital | 1 | 0 | 1 | 2021 |
9 organizations
Page 1 / 1